Therapeutic Options for Patients who are not Eligible for Intensive Chemotherapy

por Estey, Elihu
Publicado 2013

Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal

por Estey, Elihu, Hasserjian, Robert P., Döhner, Hartmut
Publicado 2022

Improved outcomes with “7+3” induction chemotherapy for acute myeloid leukemia over the past four decades: analysis of SWOG trial data

por Othus, Megan, Garcia-Manero, Guillermo, Godwin, John E., Weick, James K., Appelbaum, Frederick R., Erba, Harry P., Estey, Elihu H.
Publicado 2022

Impact of region of diagnosis, ethnicity, age, and gender on survival in acute myeloid leukemia (AML)

por Acharya, Utkarsh H., Halpern, Anna B., Wu, Qian (Vicky), Voutsinas, Jenna M., Walter, Roland B., Yun, Seongseok, Kanaan, Mohammed, Estey, Elihu H.
Publicado 2018

Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia

por Cortes, Jorge E., de Lima, Marcos, Dombret, Hervé, Estey, Elihu H., Giralt, Sergio A., Montesinos, Pau, Röllig, Christoph, Venditti, Adriano, Wang, Eunice S.
Publicado 2020

Comparison between measurable residual disease relapse and morphologic relapse in acute myeloid leukemia and high-grade myeloid neoplasms

por Shih, Lauren, Othus, Megan, Schonhoff, Kelda, Shaw, Carole, Appelbaum, Jacob, Halpern, Anna B., Becker, Pamela S., Walter, Roland B., Estey, Elihu, Percival, Mary-Elizabeth
Publicado 2023

Effect of Measurable (“Minimal”) Residual Disease (MRD) Information on Prediction of Relapse and Survival in Adult Acute Myeloid Leukemia

por Othus, Megan, Wood, Brent L., Stirewalt, Derek L., Estey, Elihu H., Petersdorf, Stephen H., Appelbaum, Frederick R., Erba, Harry P., Walter, Roland B.
Publicado 2016

Regimen‐intensity per count‐recovery and hospitalization index: A new tool to assign regimen intensity for AML

por Sorror, Mohamed L., Agarwal, Shirali, Othus, Megan, Lynch, Ylinne, Nyland, Jennifer E., Percival, Mary‐Elizabeth, Becker, Pamela S., Appelbaum, Frederick R., Estey, Elihu H.
Publicado 2020

Pre- and Post-Transplant Quantification of Measurable (“Minimal”) Residual Disease via Multiparameter Flow Cytometry in Adult Acute Myeloid Leukemia

por Zhou, Yi, Othus, Megan, Araki, Daisuke, Wood, Brent L., Radich, Jerald P., Halpern, Anna B., Mielcarek, Marco, Estey, Elihu H., Appelbaum, Frederick R., Walter, Roland B.
Publicado 2016

Effect of ECOG performance status on outcomes in patients with acute myeloid leukemia and other high-grade myeloid neoplasms

por Paras, Gabrielle, Othus, Megan, Schonhoff, Kelda, Shaw, Carole, Sorror, Mohamed, Halpern, Anna B., Appelbaum, Jacob, Hendrie, Paul, Walter, Roland B., Estey, Elihu H., Percival, Mary-Elizabeth M.
Publicado 2022

Prognostic impact of secondary versus de novo ontogeny in acute myeloid leukemia is accounted for by the European LeukemiaNet 2022 risk classification

por Hochman, Michael J., Othus, Megan, Hasserjian, Robert P., Ambinder, Alex, Brunner, Andrew, Percival, Mary-Elizabeth M., Hourigan, Christopher S., Swords, Ronan, DeZern, Amy E., Estey, Elihu H., Karp, Judith E.
Publicado 2023

Effect of Genetic Profiling on Prediction of Therapeutic Resistance and Survival in Adult Acute Myeloid Leukemia

por Walter, Roland B., Othus, Megan, Paietta, Elisabeth M., Racevskis, Janis, Fernandez, Hugo F., Lee, Ju-Whei, Sun, Zhuoxin, Tallman, Martin S., Patel, Jay, Gönen, Mithat, Abdel-Wahab, Omar, Levine, Ross L., Estey, Elihu H.
Publicado 2015

A machine learning approach to integrate big data for precision medicine in acute myeloid leukemia

por Lee, Su-In, Celik, Safiye, Logsdon, Benjamin A., Lundberg, Scott M., Martins, Timothy J., Oehler, Vivian G., Estey, Elihu H., Miller, Chris P., Chien, Sylvia, Dai, Jin, Saxena, Akanksha, Blau, C. Anthony, Becker, Pamela S.
Publicado 2018

Resistance Prediction in AML: Analysis of 4,601 Patients from MRC/NCRI, HOVON/SAKK, SWOG, and MD Anderson Cancer Center

por Walter, Roland B., Othus, Megan, Burnett, Alan K., Löwenberg, Bob, Kantarjian, Hagop M., Ossenkoppele, Gert J., Hills, Robert K., Ravandi, Farhad, Pabst, Thomas, Evans, Anna, Pierce, Sherry R., Vekemans, Marie-Christiane, Appelbaum, Frederick R., Estey, Elihu H.
Publicado 2014

Accurate Detection of Uniparental Disomy and Microdeletions by SNP Array Analysis in Myelodysplastic Syndromes with Normal Cytogenetics

por Heinrichs, Stefan, Kulkarni, Rima V., Bueso-Ramos, Carlos E., Levine, Ross L., Loh, Mignon L., Li, Cheng, Neuberg, Donna, Kornblau, Steven M., Issa, Jean-Pierre, Gilliland, D. Gary, Garcia-Manero, Guillermo, Kantarjian, Hagop M., Estey, Elihu H., Look, A. Thomas
Publicado 2009

Phase 1/2 Trial of CLAG-M with Dose-Escalated Mitoxantrone in Combination with Fractionated-Dose Gemtuzumab Ozogamicin for Newly Diagnosed Acute Myeloid Leukemia and Other High-Gra...

por Godwin, Colin D., Rodríguez-Arbolí, Eduardo, Othus, Megan, Halpern, Anna B., Appelbaum, Jacob S., Percival, Mary-Elizabeth M., Hendrie, Paul C., Oehler, Vivian G., Keel, Siobán B., Abkowitz, Janis L., Cooper, Jason P., Cassaday, Ryan D., Estey, Elihu H., Walter, Roland B.
Publicado 2022

PR1 Peptide Vaccine Induces Specific Immunity With Clinical Responses In Myeloid Malignancies

por Qazilbash, Muzaffar H., Wieder, Eric, Thall, Peter F., Wang, Xuemei, Rios, Rosa, Lu, Sijie, Kanodia, Shreya, Ruisaard, Kathryn E., Giralt, Sergio A., Estey, Elihu H., Cortes, Jorge, Komanduri, Krishna V., Clise-Dwyer, Karen, Alatrash, Gheath, Ma, Qing, Champlin, Richard E., Molldrem, Jeffrey J.
Publicado 2016

Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neo...

por Halpern, Anna B., Othus, Megan, Huebner, Emily M., Buckley, Sarah A., Pogosova-Agadjanyan, Era L., Orlowski, Kaysey F., Scott, Bart L., Becker, Pamela S., Hendrie, Paul C., Chen, Tara L., Percival, Mary-Elizabeth M., Estey, Elihu H., Stirewalt, Derek L., Walter, Roland B.
Publicado 2017

Development and Validation of a Novel Acute Myeloid Leukemia–Composite Model to Estimate Risks of Mortality

por Sorror, Mohamed L., Storer, Barry E., Fathi, Amir T., Gerds, Aaron T., Medeiros, Bruno C., Shami, Paul, Brunner, Andrew M., Sekeres, Mikkael A., Mukherjee, Sudipto, Peña, Esteban, Elsawy, Mahmoud, Wardyn, Shylo, Whitten, Jennifer, Moore, Rachelle, Becker, Pamela S., McCune, Jeannine S., Appelbaum, Frederick R., Estey, Elihu H.
Publicado 2017

Phase 1/2 Trial of GCLAM with Dose-Escalated Mitoxantrone for Newly Diagnosed AML or Other High-Grade Myeloid Neoplasms

por Halpern, Anna B., Othus, Megan, Huebner, Emily M., Scott, Bart L., Becker, Pamela S., Percival, Mary-Elizabeth M., Hendrie, Paul C., Gardner, Kelda M., Chen, Tara L., Buckley, Sarah A., Orlowski, Kaysey F., Anwar, Asma, Appelbaum, Frederick R., Erba, Harry P., Estey, Elihu H., Walter, Roland B.
Publicado 2018